Form 4: Pfizer CEO Bourla Acquires Phantom Stock Units

Pfizer Chairman and CEO Albert Bourla acquired 21 phantom stock units through a deferred compensation plan, increasing his beneficial ownership to 759,049 units.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., acquired 21 phantom stock units.
• The acquisition occurred on March 31, 2026, at a price of $28.08 per unit.
• These units were obtained pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Following this transaction, Bourla beneficially owns a total of 759,049 phantom stock units.
• Each phantom unit represents one phantom share of common stock and will be settled in cash following Bourla's separation from service.
• The reporting person may transfer these units into an alternative investment account at any time.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as the CEO's acquisition of additional phantom stock units, even through a compensation plan, suggests continued alignment with shareholder interests.

Positives

• The acquisition of additional phantom stock units by the CEO indicates continued alignment of management's interests with shareholder value.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

StockSavvy.ai notes that insider acquisitions, even of phantom units through deferred compensation plans, can signal management's confidence in the company's long-term prospects, aligning their personal financial interests with the company's performance within the pharmaceutical industry.

Comparison to Industry Standards

• This is a routine insider transaction report. Direct comparisons to specific companies or projects are not applicable here, as it reflects an individual's compensation and ownership structure rather than operational performance or strategic initiatives.

Related Party Transactions

• Acquisition of 21 phantom stock units by CEO Albert Bourla through the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.

Stakeholder Impact

• Shareholders: The CEO's increased beneficial ownership aligns his interests with shareholders, potentially fostering confidence.
• Employees: The deferred compensation plan is part of executive compensation, which can influence executive morale and retention.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where the CEO acquired phantom stock units as part of a deferred compensation plan. While it indicates continued alignment of management's interests with the company, it does not provide new fundamental information about Pfizer's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Pfizer, PFE, Albert Bourla, Insider Transaction, Form 4, Phantom Stock Units, Deferred Compensation, CEO, Stock Acquisition